Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07000019 · ClinicalTrials.gov registry record · NA
Combined Aphasia and Robot-Assisted Arm Treatment for Chronic Stroke Survivors
A NA study, sponsored by New York Medical College.
- Not yet
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT07000019: Clinical Trial NA study, sponsored by New York Medical College.
NCT07000019 is a NA study that has not yet begun recruiting, run by New York Medical College. The registered enrollment target is 28 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07000019, a NA study, has not yet begun recruiting, sponsored by New York Medical College.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if a program that combines language and arm treatment can improve language and movement problems in people with chronic stroke. The mains questions it aims to answer are: * To determine the extent to which this combined treatment can improve language. * To determine the extent to which the combined treatment can improve arm movements. Researchers will compare the effects of this combined treatment with treatment that targets arm movements alone.
Interventions
- BEHAVIORAL CARAT: combined aphasia and robot-assisted arm therapy
- BEHAVIORAL Robot-assisted arm therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2025-06 |
| Est. Completion | 2027-11 |
| Phase | NA |
What is known before NCT07000019 opens enrollment
NCT07000019 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which CARAT: combined aphasia and robot-assisted arm therapy is the first listed.
NCT07000019 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07000019 about?
NCT07000019 is a clinical study titled "Combined Aphasia and Robot-Assisted Arm Treatment for Chronic Stroke Survivors". The goal of this clinical trial is to learn if a program that combines language and arm treatment can improve language and movement problems in people with chronic stroke. The mains questions it aims to answer are: * To determine the extent to which this combined treatment can improve language. * T...
What is the current status of trial NCT07000019?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 28 participants. The study started on 2025-06. Estimated completion is 2027-11.
What interventions are being tested in trial NCT07000019?
The interventions under investigation include: CARAT: combined aphasia and robot-assisted arm therapy (BEHAVIORAL), Robot-assisted arm therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT07000019?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07000019's enrollment target sits among peer trials
28 1704th of 2000 higher than 293 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia